Ciliary Body and Choroid Melanoma, Medium/Large Size
11
0
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
9.1%
1 terminated out of 11 trials
90.0%
+3.5% vs benchmark
0%
0 trials in Phase 3/4
67%
6 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (11)
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma